Elinzanetant Explained

Elinzanetant (developmental code names BAY-3427080 GSK-1144814, NT-814) is an orally active small-molecule neurokinin/tachykinin NK₁ receptor and NK₃ receptor antagonist which is under development by Bayer, GlaxoSmithKline, and NeRRe Therapeutics for the treatment of hot flashes and "sex hormone disorders".^{[1] [2]} It has been found to relieve hot flashes in postmenopausal women and to dose-dependently suppress luteinizing hormone, estradiol, and progesterone levels in premenopausal women.^[3] As of August 2021, elinzanetant is in phase 2 clinical trials for hot flashes and "sex hormone disorders". It was also under development for the treatment of schizophrenia and opioid-related disorders, but development was discontinued for these uses.

See also

• List of investigational sex-hormonal agents § Neurokinin/tachykinin receptor antagonists

External links

• Elinzanetant - AdisInsight

Notes and References

1. Web site: Elinzanetant - Bayer . Adis Insight . Springer Nature Switzerland AG .
2. Depypere H, Lademacher C, Siddiqui E, Fraser GL . Fezolinetant in the treatment of vasomotor symptoms associated with menopause . Expert Opinion on Investigational Drugs . 30 . 7 . 681–694 . July 2021 . 33724119 . 10.1080/13543784.2021.1893305 . free . 1854/LU-8758954 . free .
3. Pawsey S, Mills EG, Ballantyne E, Donaldson K, Kerr M, Trower M, Dhillo WS . Elinzanetant (NT-814), a Neurokinin 1,3 Receptor Antagonist, Reduces Estradiol and Progesterone in Healthy Women . The Journal of Clinical Endocrinology and Metabolism . 106 . 8 . e3221–e3234 . July 2021 . 33624806 . 8277204 . 10.1210/clinem/dgab108 .